Sermorelin
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
What is it?
Sermorelin is GHRH(1-29) — the working business end of your own growth-hormone-releasing hormone. Researchers found that the first 29 of GHRH’s 44 amino acids carry the full GH-releasing activity, so sermorelin is that fragment, synthesized. It binds your pituitary’s GHRH receptor and triggers a normal, pulsatile GH release.
The key idea: sermorelin doesn’t give you growth hormone. It asks your pituitary to make its own. That’s the physiologic way to do it — your body keeps the dimmer switch (somatostatin feedback) so the system self-regulates, releasing GH in the natural pulses it’s built around rather than the non-pulsatile flood of injected HGH. Among the GHRH family, sermorelin is the short, gentle, most-natural-mimicking member: compare it to CJC-1295 with-DAC (engineered for a multi-day half-life) or Tesamorelin (the FDA-approved, longer-acting GHRH cousin).
And here’s what sets sermorelin apart from everything else in this GH-axis set: it was once a real, fully FDA-approved drug, with a clinical dossier behind it. That gives it a more legitimate paper trail than most peptides in this space.
What does it do in my body?
Natural GHRH is a 44-amino-acid hormone your hypothalamus releases to tell your pituitary, “release a GH pulse.” The active core lives in the first 29 amino acids — so sermorelin is GHRH(1-29). It binds the GHRH receptor on the anterior pituitary, triggers the standard cascade (calcium influx, cyclic-AMP), and the pituitary releases GH in a pulse.
Two features make it elegant. First, because it works upstream, your negative-feedback loop stays intact — somatostatin (your body’s GH brake) is still in play, so you get physiologic pulses rather than a flooded system. Second, its half-life is only ~10–12 minutes, so the signal is a quick tap, not a sustained shove. That short action is exactly why it’s dosed at night — to ride and amplify your natural overnight GH pulse, which is when most of your GH is released anyway.
How can it help me?
The original GHRH peptide — the first 29 amino acids of your own growth-hormone-releasing hormone, and the only peptide in this GH-axis set that was once a fully FDA-approved drug. The gentlest, most physiologic way to ask your pituitary to make its own GH. Backed by real human RCT data.
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
In the pediatric trials and the long Geref track record, sermorelin was well tolerated — which is a meaningful real-world dataset most peptides don’t have.
What’s reported: injection-site reactions, facial flushing, headache, occasional nausea or dizziness — generally mild and self-limiting. Nearly all treated children developed anti-GHRH antibodies, which resolved after stopping and didn’t appear to impair growth; their long-term significance in adults is simply unstudied.
One preclinical signal worth knowing about, in context: a 2022 in-vitro and mouse-xenograft study found GHRH could transform non-tumor prostate epithelial cells and drive tumor formation in mice — a theoretical prostate signal for GHRH agonists as a class. Keep this in proportion: it’s a cell-and-mouse finding at doses and contexts that differ from therapeutic use, with no human clinical confirmation. It’s reasonable to fold routine prostate monitoring into a longer-term protocol for older men (sensible regardless of peptides), and active cancer is the standard conservative contraindication. Worth knowing, not worth alarm.
The broader GH-axis frame: as with the other secretagogues, keep IGF-1 in your age-adjusted physiologic range and check it periodically on longer runs. Sermorelin’s upstream, pulse-preserving mechanism — your somatostatin brake stays intact — is exactly why this category is considered more physiologic than exogenous HGH. And as Bakri and one practitioner both emphasize, the dominant real-world variable for any peptide is sourcing quality, not the molecule.
Regulatory status: Here’s the honest history. Sermorelin was FDA-approved as Geref in 1997 for diagnosing and treating pediatric GH deficiency. The manufacturer (EMD Serono) notified the FDA in December 2008 that Geref was being discontinued: for commercial reasons, not safety. The FDA later formally confirmed this: in a 2013 Federal Register determination it found that Geref injection “was not withdrawn from sale for reasons of safety or effectiveness”. That distinction matters: it wasn’t pulled for harming anyone. The consequence is that today there’s no FDA-approved sermorelin product; what’s sold is compounded or research-grade, used off-label, and WADA-prohibited in sport.
Part 1 — How to reconstitute it
What you'll need: bacteriostatic water (sterile, preserved water you mix the powder with) and a separate, larger reconstitution syringe just for mixing — not the small syringe you inject with.
The exact bacteriostatic-water volume and resulting concentration for Sermorelin are covered in the dosing notes and the deeper-science view. Confirm the right volume for your vial before mixing.
How to mix it
- Tilt the vial and let the bacteriostatic water run slowly down the inside glass wall — never squirt it straight onto the powder.
- Swirl gently to dissolve. Never shake — shaking can damage the peptide.
- Store the reconstituted vial refrigerated and out of light.
- Use it within the beyond-use window your source specifies — reconstituted peptides are commonly used within a few weeks; confirm the window for your specific peptide.
Use the free reconstitution calculator to turn any vial size + water volume into exact units on an insulin syringe.
Part 2 — Typical dosing
Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.
The syringe. Use a 0.3 mL U-100 insulin syringe — it's sized for these small subcutaneous doses. Inject subcutaneously (into the fat just under the skin) and rotate injection sites.
This is the protocol the community and practitioners use, alongside the trial-derived pediatric dose for reference.
Standard adult protocol:
- Dose: roughly 200–300 mcg subcutaneously, nightly, on an empty stomach
- Schedule: ~5 nights/week, cycled
- Reconstitution: a 5 mg vial + 2.5 ml bacteriostatic water = 2,000 mcg/ml. A 300 mcg dose = 0.15 ml = 15 units on a U-100 insulin syringe. Always confirm your vial size and target dose before drawing.
- Reference (trial dose): the pediatric trial dose was 30 µg/kg subcutaneously at bedtime.
Timing: Dose at night, fasted. Sermorelin’s ~10–12-minute half-life is the reason — you want the GH pulse to land on top of your natural overnight surge, and food (especially carbs/fat) near the dose blunts the GH response.
Cycling: Community default is cycled blocks (e.g., ~5 nights/week, with periodic breaks) to keep the GHRH receptor responsive — consistent with the general GH-axis cycling principle of not running these signals continuously indefinitely.
What should I avoid combining — and what's synergistic?
⚠️ If you’re stacking with a GLP-1 receptor agonist (Retatrutide, Semaglutide, Tirzepatide), the standard “2 hours after eating” rule isn’t long enough. GLP-1 activity slows gastric emptying — food sits in the stomach for ~3 hours rather than 2. Residual insulin from dinner suppresses the GH pulse at the pituitary, so the “dinner at 7, pin at 9” convention fails on a GLP-1. Move sermorelin to first thing in the morning when on a GLP-1, and eat 30-60 min after injection. Full rule + sources in Retatrutide § Stacking.
Stacking: Sermorelin is often run alone as the gentlest GHRH option, or paired with a ghrelin-receptor agonist like Ipamorelin on the same dual-receptor logic that drives the CJC-1295 / Ipamorelin blend (GHRH signal + ghrelin pulse = bigger combined GH release). For a longer-acting GHRH baseline, people step up to CJC-1295 with-DAC instead.
How can I buy this?
Alyve lists Sermorelin at $22.99–$46.00 (2 mg / 5 mg), currently showing out of stock, with no standalone COA captured on disk yet for this SKU. Alyve’s own copy stays appropriately dry — “synthetic GHRH(1-29) analog studied in endocrine-axis and somatotroph signaling models,” no anti-aging hype.
For context on what Alyve’s testing looks like when a product is in stock: their tested SKUs run >99% purity via Freedom Diagnostics Testing (independent third party, HPLC-UV + LC-MS identity confirmation) — for example the in-stock CJC-1295 + Ipamorelin blend at 99.90% (lot CJI583). That verified-clean tier is the thing to look for, because the gray-market peptide supply chain is batch-to-batch unknown for both purity and identity.
Offer (when restocked): coupon OHM-15 is 15% off — Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. (Full disclosure: OHM-15 attributes the sale to me — said plainly.)
When you use my coupon code to buy peptides with these sellers, you enjoy a discount off retail price, and I make a small commission which helps me to continue to offer this peptide educational site to you for free. I only have affiliate relationships with peptide manufacturers that show evidence that their peptides are 100% manufactured in the US, 3rd party lab tested for purity, transparent COAs posted on their websites, and that have good customer service.
The original GHRH peptide — the first 29 amino acids of your own growth-hormone-releasing hormone, and the only peptide in this GH-axis set that was once a fully FDA-approved drug. The gentlest, most physiologic way to ask your pituitary to make its own GH. Backed by real human RCT data.
| Class | Growth-hormone-releasing hormone (GHRH) analog — the active first 29 amino acids of natural GHRH |
| Mechanism (one-liner) | Flips your pituitary’s natural GHRH switch so you make GH in normal pulses — never injects GH directly |
| Route | Subcutaneous injection, usually at bedtime |
| Half-life | ~10–12 minutes — very short, which is the whole point |
| Evidence | Pediatric GH-deficiency RCTs [PMIDs 8329830, 8329826]; large open-label trials [PMID 8772599]; FDA-approval dossier; adult use extrapolated |
| Regulatory status | Formerly FDA-approved (Geref, 1997); voluntarily discontinued ~2008 for commercial reasons. Now compounded/RUO. WADA-prohibited. |
| Alyve product | Sermorelin, $22.99–$46.00 (currently out of stock) |
| Primary OHM use case | The “make-your-own-GH” peptide for sleep, recovery, and anti-aging — the most physiologic GHRH option |
What it is
Sermorelin is GHRH(1-29) — the working business end of your own growth-hormone-releasing hormone. Researchers found that the first 29 of GHRH’s 44 amino acids carry the full GH-releasing activity, so sermorelin is that fragment, synthesized. It binds your pituitary’s GHRH receptor and triggers a normal, pulsatile GH release.
The key idea: sermorelin doesn’t give you growth hormone. It asks your pituitary to make its own. That’s the physiologic way to do it — your body keeps the dimmer switch (somatostatin feedback) so the system self-regulates, releasing GH in the natural pulses it’s built around rather than the non-pulsatile flood of injected HGH. Among the GHRH family, sermorelin is the short, gentle, most-natural-mimicking member: compare it to CJC-1295 with-DAC (engineered for a multi-day half-life) or Tesamorelin (the FDA-approved, longer-acting GHRH cousin).
And here’s what sets sermorelin apart from everything else in this GH-axis set: it was once a real, fully FDA-approved drug, with a clinical dossier behind it. That gives it a more legitimate paper trail than most peptides in this space.
How it works
Natural GHRH is a 44-amino-acid hormone your hypothalamus releases to tell your pituitary, “release a GH pulse.” The active core lives in the first 29 amino acids — so sermorelin is GHRH(1-29). It binds the GHRH receptor on the anterior pituitary, triggers the standard cascade (calcium influx, cyclic-AMP), and the pituitary releases GH in a pulse.
Two features make it elegant. First, because it works upstream, your negative-feedback loop stays intact — somatostatin (your body’s GH brake) is still in play, so you get physiologic pulses rather than a flooded system. Second, its half-life is only ~10–12 minutes, so the signal is a quick tap, not a sustained shove. That short action is exactly why it’s dosed at night — to ride and amplify your natural overnight GH pulse, which is when most of your GH is released anyway.
What the research shows
Sermorelin actually has genuine human RCT data — more than most peptides in this category. Here’s the full picture, every tier labeled, strongest first.
Pediatric GH deficiency: the strongest evidence. Two randomized controlled trials [PMIDs 8329830, 8329826] plus large open-label multicenter trials [PMIDs 8772599, 18031173] show sermorelin meaningfully increased height velocity in GH-deficient children. In the Geref International study, height velocity roughly doubled (e.g., 4.1 → 8.0 cm/yr). It produced less growth than direct GH (somatropin) but clearly outperformed no treatment. This is FDA-dossier-grade human evidence that the molecule does what it’s designed to do: drive real, measurable GH-dependent outcomes in people.
Diagnostic use. Sermorelin as a GH-stimulation test is well-characterized in humans going back to the 1980s [PMIDs 18031173, 2863206] — more confirmation the GHRH-receptor mechanism reliably releases GH in people.
Adult GH-axis use. The best adult human data is a retrospective chart review of 14 hypogonadal men in which sermorelin (given alongside GHRP-2 and GHRP-6) raised IGF-1 [PMID 28830317]. Because it was co-administered, you can’t fully isolate sermorelin’s solo contribution — but it’s consistent with the mechanism. Adult body-composition, sleep, energy, and anti-aging outcomes are extrapolated from the pediatric RCT data, the diagnostic human data, and GH/IGF-1 physiology rather than from a dedicated adult RCT. A 2020 review of GH secretagogues in hypogonadal men frames the adult evidence base as still developing.
The honest map: sermorelin has real human RCT proof that it works (in growth-deficient kids), a long real-world safety track record from its Geref years, and an adult anti-aging case that’s mechanistically sound and extrapolated rather than separately RCT-proven. The adult body-comp logic doesn’t float free, though — it rests on verified GH-replacement evidence: Rudman’s landmark 1990 NEJM RCT (GH in older men improved lean mass, reduced fat, raised skin/bone density) and Brioche 2014 (GH prevents sarcopenia + mitochondrial biogenesis in aged rats). Sermorelin’s job is to raise your own GH toward that physiologic range. For a GH-axis peptide, that’s a strong evidence position — among the strongest in this set.
Real-world protocol
The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.
This is the protocol the community and practitioners use, alongside the trial-derived pediatric dose for reference.
Standard adult protocol:
- Dose: roughly 200–300 mcg subcutaneously, nightly, on an empty stomach
- Schedule: ~5 nights/week, cycled
- Reconstitution: a 5 mg vial + 2.5 ml bacteriostatic water = 2,000 mcg/ml. A 300 mcg dose = 0.15 ml = 15 units on a U-100 insulin syringe. Always confirm your vial size and target dose before drawing.
- Reference (trial dose): the pediatric trial dose was 30 µg/kg subcutaneously at bedtime.
Timing: Dose at night, fasted. Sermorelin’s ~10–12-minute half-life is the reason — you want the GH pulse to land on top of your natural overnight surge, and food (especially carbs/fat) near the dose blunts the GH response.
⚠️ If you’re stacking with a GLP-1 receptor agonist (Retatrutide, Semaglutide, Tirzepatide), the standard “2 hours after eating” rule isn’t long enough. GLP-1 activity slows gastric emptying — food sits in the stomach for ~3 hours rather than 2. Residual insulin from dinner suppresses the GH pulse at the pituitary, so the “dinner at 7, pin at 9” convention fails on a GLP-1. Move sermorelin to first thing in the morning when on a GLP-1, and eat 30-60 min after injection. Full rule + sources in Retatrutide § Stacking.
Stacking: Sermorelin is often run alone as the gentlest GHRH option, or paired with a ghrelin-receptor agonist like Ipamorelin on the same dual-receptor logic that drives the CJC-1295 / Ipamorelin blend (GHRH signal + ghrelin pulse = bigger combined GH release). For a longer-acting GHRH baseline, people step up to CJC-1295 with-DAC instead.
Cycling: Community default is cycled blocks (e.g., ~5 nights/week, with periodic breaks) to keep the GHRH receptor responsive — consistent with the general GH-axis cycling principle of not running these signals continuously indefinitely.
Side effects & management
In the pediatric trials and the long Geref track record, sermorelin was well tolerated — which is a meaningful real-world dataset most peptides don’t have.
What’s reported: injection-site reactions, facial flushing, headache, occasional nausea or dizziness — generally mild and self-limiting. Nearly all treated children developed anti-GHRH antibodies, which resolved after stopping and didn’t appear to impair growth; their long-term significance in adults is simply unstudied.
One preclinical signal worth knowing about, in context: a 2022 in-vitro and mouse-xenograft study found GHRH could transform non-tumor prostate epithelial cells and drive tumor formation in mice — a theoretical prostate signal for GHRH agonists as a class. Keep this in proportion: it’s a cell-and-mouse finding at doses and contexts that differ from therapeutic use, with no human clinical confirmation. It’s reasonable to fold routine prostate monitoring into a longer-term protocol for older men (sensible regardless of peptides), and active cancer is the standard conservative contraindication. Worth knowing, not worth alarm.
The broader GH-axis frame: as with the other secretagogues, keep IGF-1 in your age-adjusted physiologic range and check it periodically on longer runs. Sermorelin’s upstream, pulse-preserving mechanism — your somatostatin brake stays intact — is exactly why this category is considered more physiologic than exogenous HGH. And as Bakri and one practitioner both emphasize, the dominant real-world variable for any peptide is sourcing quality, not the molecule.
Regulatory status
Here’s the honest history. Sermorelin was FDA-approved as Geref in 1997 for diagnosing and treating pediatric GH deficiency. The manufacturer (EMD Serono) notified the FDA in December 2008 that Geref was being discontinued: for commercial reasons, not safety. The FDA later formally confirmed this: in a 2013 Federal Register determination it found that Geref injection “was not withdrawn from sale for reasons of safety or effectiveness”. That distinction matters: it wasn’t pulled for harming anyone. The consequence is that today there’s no FDA-approved sermorelin product; what’s sold is compounded or research-grade, used off-label, and WADA-prohibited in sport.
The Alyve product
Alyve lists Sermorelin at $22.99–$46.00 (2 mg / 5 mg), currently showing out of stock, with no standalone COA captured on disk yet for this SKU. Alyve’s own copy stays appropriately dry — “synthetic GHRH(1-29) analog studied in endocrine-axis and somatotroph signaling models,” no anti-aging hype.
For context on what Alyve’s testing looks like when a product is in stock: their tested SKUs run >99% purity via Freedom Diagnostics Testing (independent third party, HPLC-UV + LC-MS identity confirmation) — for example the in-stock CJC-1295 + Ipamorelin blend at 99.90% (lot CJI583). That verified-clean tier is the thing to look for, because the gray-market peptide supply chain is batch-to-batch unknown for both purity and identity.
Offer (when restocked): coupon OHM-15 is 15% off — Alyve’s pricing is very competitive, and buying 3 vials of any given peptide in one purchase gets you over 30% off retail. (Full disclosure: OHM-15 attributes the sale to me — said plainly.)
Sources
- Chen RG, et al. GH vs GHRH(1-29) in GH-deficient children — RCT. Acta Paediatr Suppl. 1993. : 8329830
- Neyzi O, et al. Growth response to GHRH(1-29) vs GH — RCT. Acta Paediatr Suppl. 1993. : 8329826
- Thorner M, et al. Once-daily SC GHRH accelerates growth in GHD children (Geref Intl). J Clin Endocrinol Metab. 1996. : 8772599
- Prakash A, Goa KL. Sermorelin: review (Geref dossier). BioDrugs. 1999. : 18031173
- Sigalos JT, et al. GH secretagogue (incl. sermorelin) raises IGF-1 in hypogonadal men. Am J Mens Health. 2017. : 28830317
- Muñoz-Moreno L, et al. GHRH transforms prostate epithelial cells (RWPE-1) / xenograft. Prostate. 2022. : 35322894
- Sinha DK, et al. GH secretagogues in hypogonadal males — review. Transl Androl Urol. 2020. : 32257855
- Rudman D, et al. Effects of human growth hormone in men over 60 (foundational GH body-comp RCT). N Engl J Med. 1990. : 2355952
- Brioche T, et al. GH replacement prevents sarcopenia + mitochondrial biogenesis (rat). J Gerontol A Biol Sci Med Sci. 2014. : 24300031
- Wikipedia — Sermorelin (half-life, Geref history). https://en.wikipedia.org/wiki/Sermorelin 10a. FDA. Determination that GEREF (sermorelin acetate) injection was not withdrawn for reasons of safety or effectiveness. Federal Register 78 FR 14122, Mar 4 2013. https://www.federalregister.gov/documents/2013/03/04/2013-04827/
- Dosing/reconstitution cheat sheet (one practitioner).
- Alyve COA summary (Freedom Diagnostics, >99% across tested SKUs).
- Alyve Peptides — Sermorelin product page. / https://alyvepeptides.com/product/sermorelin/
See also: CJC-1295, Ipamorelin, CJC-1295 / Ipamorelin, Tesamorelin.
Sources & references
- Chen RG, et al. GH vs GHRH(1-29) in GH-deficient children — RCT. Acta Paediatr Suppl. 1993. : 8329830
- Neyzi O, et al. Growth response to GHRH(1-29) vs GH — RCT. Acta Paediatr Suppl. 1993. : 8329826
- Thorner M, et al. Once-daily SC GHRH accelerates growth in GHD children (Geref Intl). J Clin Endocrinol Metab. 1996. : 8772599
- Prakash A, Goa KL. Sermorelin: review (Geref dossier). BioDrugs. 1999. : 18031173
- Sigalos JT, et al. GH secretagogue (incl. sermorelin) raises IGF-1 in hypogonadal men. Am J Mens Health. 2017. : 28830317
- Muñoz-Moreno L, et al. GHRH transforms prostate epithelial cells (RWPE-1) / xenograft. Prostate. 2022. : 35322894
- Sinha DK, et al. GH secretagogues in hypogonadal males — review. Transl Androl Urol. 2020. : 32257855
- Rudman D, et al. Effects of human growth hormone in men over 60 (foundational GH body-comp RCT). N Engl J Med. 1990. : 2355952
- Brioche T, et al. GH replacement prevents sarcopenia + mitochondrial biogenesis (rat). J Gerontol A Biol Sci Med Sci. 2014. : 24300031
- Wikipedia — Sermorelin (half-life, Geref history). https://en.wikipedia.org/wiki/Sermorelin 10a. FDA. Determination that GEREF (sermorelin acetate) injection was not withdrawn for reasons of safety or effectiveness. Federal Register 78 FR 14122, Mar 4 2013. https://www.federalregister.gov/documents/2013/03/04/2013-04827/
- Dosing/reconstitution cheat sheet (one practitioner).
- Alyve COA summary (Freedom Diagnostics, >99% across tested SKUs).
- Alyve Peptides — Sermorelin product page. / https://alyvepeptides.com/product/sermorelin/
See also: CJC-1295, Ipamorelin, CJC-1295 / Ipamorelin, Tesamorelin.